<!doctype html>
<html lang="en"><head>
<meta charset="utf-8"/><meta name="viewport" content="width=device-width,initial-scale=1"/>
<link rel="stylesheet" href="/newsletter/style.css"/>
<title>Merck Says Phase 2 Study of Potential Lung Cancer Drug Showed &#x27;Clinically Meaningful&#x27; Response Rates — Newsletter</title>
</head><body>
<div class="container">
  <div class="header">
    <h1 style="margin:0;font-size:28px">Newsletter</h1>
    <a class="btn" href="/newsletter/">Home</a>
  </div>
  <div class="card">
    <h2 style="margin-top:0">Merck Says Phase 2 Study of Potential Lung Cancer Drug Showed &#x27;Clinically Meaningful&#x27; Response Rates</h2>
    <div class="badge">2025-09-08T09:35:03+00:00</div>
    <ul>
      <li>Merck Says Phase 2 Study of Potential Lung Cancer Drug Showed &#x27;Clinically Meaningful&#x27; Response Rates Merck (MRK) said Sunday that results from its IDeate-Lung01 phase 2 trial evaluating ifinatamab deru Upgrade to read th</li>
<li>A Silver or Gold subscription plan is required to access premium news articles.</li>
    </ul>
    <p>
      <a class="btn" href="https://twitter.com/intent/tweet?text=Merck Says Phase 2 Study of Potential Lung Cancer Drug Showed &amp;#x27;Clinically Meaningful&amp;#x27; Response Rates\n• Merck Says Phase 2 Study of Potential Lung Cancer Drug Showed &#x27;Clinically Meaningful&#x27; Response Rates Merck (MRK) said Sunday that results from its IDeate-Lung01 phase 2 trial evaluating ifinatamab deru Upgrade to read th\n• A Silver or Gold subscription plan is required to access premium news articles." target="_blank" rel="noopener">Tweet bullets</a>
      &nbsp;&nbsp;
      <a href="https://finance.yahoo.com/news/merck-says-phase-2-study-093503293.html" target="_blank" rel="noopener nofollow">finance.yahoo.com</a>
    </p>
  </div>
  <div class="footer">Built from digest_5bullets.md</div>
</div>
</body></html>